GlobeNewswire

TOUAX SCA announces that its subsidiary Touax Rail Ltd successfully signed a €81.9 million capital increase to accelerate the development of its freight railcar division in Europe and Asia

Share

PRESS RELEASE                                                                                                                           Paris, August 10th, 2020. 5:45pm

YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION

TOUAX SCA announces that its subsidiary Touax Rail Ltd successfully signed a €81.9 million capital increase to accelerate the development of its freight railcar division in Europe and Asia

Touax SCA announces today that its subsidiary Touax Rail Limited has entered into a final agreement with DIF Capital Partners to increase its capital by €81.9 million to accelerate the development of its long term leasing activities of freight wagons in Europe and Asia.

Touax SCA will remain the main shareholder holding 51% of the capital and 49% will be owned by its new partner DIF Capital Partners, through its DIF Core Infrastructure Fund II.

The transaction will be immediately accretive for Touax Rail Limited as proceeds will be used on the one hand to buy out minority shareholders in two special purpose companies owning c. 4,000 platforms and in Touax Rail India Limited, and to finance the Touax Rail Limited growth by acquiring new wagons. On the other hand, proceeds will be used to repay some intercompany loans to Touax SCA.

The transaction will strengthen the position of Touax Rail Limited in Europe and Asia with a fleet size of c. 6,930 platforms owned and c. 4,080 platforms managed on behalf of third parties, and increase its capacity to grow and finance the needs of its customers.

The transaction is subject to approval by the German Antitrust authorities. Touax expects to close the transaction by the end of September.

Fabrice Walewski, General Partner & CEO of Touax group, says that "We are very delighted to have DIF Capital Partners as partner to accompany the development of our long term leasing activities of freight wagons in Europe & Asia. With this transaction, Touax Rail Limited will strengthen its position in the market.”

Carl Jobst von Hoersten, partner and head of DIF Germany added: “This transaction is a unique investment providing exclusive access to the attractive railcar market. Touax Rail is a well-established, asset heavy railcar platform with a robust and resilient business model which is well-positioned for growth. We look forward working together with Touax Rail’s highly experienced management team to further grow the platform.”

TOUAX Group leases out tangible assets (freight railcars, river barges and containers) on a daily basis worldwide, both on its own account and for investors. With nearly €1.2bn in assets under management, TOUAX is one of the leading European players in the leasing of such equipment.
TOUAX SCA is listed on the EURONEXT stock market in Paris - Euronext Paris Compartment C (ISIN code: FR0000033003) - and is listed on the CAC® Small, CAC® Mid & Small and EnterNext©PEA-PME 150 indices. For further information please visit: www.touax.com

DIF Capital Partners is a leading global independent infrastructure fund manager, with €7.5 billion of assets under management across nine closed-end infrastructure funds and several co-investment vehicles. DIF Capital Partners invests in green field and operational infrastructure assets located primarily in Europe, the Americas and Australasia through two complementary strategies:

  • DIF CIF funds target equity investments in small to mid-sized infrastructure assets in the telecom, energy and transportation sectors.
  • DIF Infrastructure funds target equity investments in public-private partnerships (PPP/PFI/P3), concessions, utilities and renewable energy projects with long-term contracted or regulated income streams.

DIF has a team of over 145 professionals, based in nine offices located in Amsterdam (Schiphol), Frankfurt, London, Luxembourg, Madrid, Paris, Santiago, Sydney and Toronto. Please visit www.dif.eu for further information.

Contact details:
TOUAX                                                                                                                                                                                    ACTIFIN
Fabrice & Raphaël WALEWSKI                                                                                                                       Ghislaine Gasparetto
touax@touax.com                                                                                                                                           ggasparetto@actifin.fr
www.touax.com                                                                                                                                                 Tel: +33 1 56 88 11 11
Tel: +33 1 46 96 18 00

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation19.9.2020 16:25:00 CESTPress release

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3 Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only trea

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma19.9.2020 16:20:00 CESTPress release

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the long

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 202019.9.2020 16:20:00 CESTPress release

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapyFinal overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours expressed PD-L1 and who received Tecentriq plus nab-paclitaxelResults from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel for the treatment of people with metastatic TNBC and whose tumours expressed PD-L1, did not meet its primary endpoint of progression-free survival Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical

Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CESTPress release

Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se. Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol